How to cite item

Novel lymphocyte to red blood cell ratio (LRR), neutrophil to red blood cell ratio (NRR), monocyte to red blood cell ratio (MRR) as predictive and prognostic biomarkers for locally advanced breast cancer

  
@article{GS32510,
	author = {Yaohui Wang and Haofeng Wang and Wenjin Yin and Yanping Lin and Liheng Zhou and Xiaonan Sheng and Yaqian Xu and Rui Sha and Jinsong Lu},
	title = {Novel lymphocyte to red blood cell ratio (LRR), neutrophil to red blood cell ratio (NRR), monocyte to red blood cell ratio (MRR) as predictive and prognostic biomarkers for locally advanced breast cancer},
	journal = {Gland Surgery},
	volume = {8},
	number = {6},
	year = {2019},
	keywords = {},
	abstract = {Background: Lymphocytes, neutrophils, and monocytes are vital effector cells in innate immunity. We postulated that lymphocyte to red blood cell ratio (LRR), neutrophil to red blood cell ratio (NRR), monocyte to red blood cell ratio (MRR) could represent the intensity of systemic inflammatory immunological reaction reflected through the lymphocyte, neutrophil and monocyte respectively. This study aimed to access the predictive and prognostic value of LRR, NRR, MRR and LRR-NRR-MRR score for locally advanced breast cancer.
Methods: A total of 137 patients from two clinical trials SHPD002 and SHPD003 were included. Logistic regression analysis was used to evaluate the association between ratios and pathological complete response (pCR). Disease-free survival (DFS) and overall survival (OS) were estimated by Kaplan-Meier method and cox regression analysis.
Results: Lower LRR-NRR-MRR score (OR =0.593; 95% CI: 0.369–0.954; P=0.031) was more easily to achieve pCR in multivariate analysis. Lower LRR (P=0.022), NRR (P=0.027) and MRR (P=0.024) were significantly associated with better DFS. LRR-NRR-MRR score was an independently prognostic factor for both DFS (HR =3.318; 95% CI: 1.601–6.876; P=0.001) and OS (HR =3.160; 95% CI: 1.030–9.696; P=0.044).
Conclusions: The LRR-NRR-MRR score could be identified as a new predictive biomarker for the therapeutic effect of neoadjuvant therapy and an independent prognostic factor for both DFS and OS for locally advanced breast cancer.},
	issn = {2227-8575},	url = {https://gs.amegroups.org/article/view/32510}
}